Neogen Announces the Appointment of New Board Member
QIAGEN Launches QIAcuityDx Digital PCR System For Clinical Testing In Oncology
Those Who Invested in Qiagen (NYSE:QGEN) Five Years Ago Are up 41%
QIAGEN Receives European IVDR Certification For QIAstat-Dx Syndromic Testing Instruments And Assays
QIAGEN And BD Joint Venture, PreAnalytiX, Launches Solution For Liquid Biopsy From Urine Samples
Qiagen Insiders Sell US$7.0m Of Stock, Possibly Signalling Caution
QIAGEN and Bode Technology Partner to Advance Use of GEDmatch PRO Forensic Genetic Genealogy Database
BofA Securities Maintains Qiagen NV(QGEN.US) With Buy Rating, Announces Target Price $55
BofA Securities analyst Michael Ryskin maintains $Qiagen NV(QGEN.US)$ with a buy rating, and sets the target price at $55.According to TipRanks data, the analyst has a success rate of 57.9% and a
QIAGEN Expands QIAcuity Digital PCR Offering With Over 100 New Assays Via GeneGlobe Platform, Supporting Cancer Research, Genetic Disorders, Infectious Disease Surveillance, And Environmental Monitoring
Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?
QIAGEN and Bio-Manguinhos/Fiocruz Collaborate to Enhance Malaria and Dengue Detection in Brazil's National Screening Programs
Qiagen N.V.'s (NYSE:QGEN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
With 79% Institutional Ownership, Qiagen N.V. (NYSE:QGEN) Is a Favorite Amongst the Big Guns
QIAGEN, Lilly to Develop Alzheimer's Risk Detection Test
QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds
QIAGEN Expands Master Collaboration Agreement With AstraZeneca's Future Therapies To Develop And Validate A Genotyping Assay Using Co's Syndromic Testing Platform QIAstat-Dx
Berenberg Lifts Price Target on Qiagen to EUR54.90 From EUR54.20, Keeps Buy Rating
Express News | Qiagen NV : Morgan Stanley Raises Target Price to $49 From $47
Baird Maintains Outperform on Qiagen, Raises Price Target to $52
Qiagen Analyst Ratings